Lab-designed molecule reduces amyloid beta, the protein linked to Alzheimer's disease, in mice - Medical Xpress
A research team led by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC), in collaboration with Míriam Royo's laboratory at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona), has identified a synthetic peptide that reduces the production of amyloid beta (Aβ).
This article is an excerpt. To read the full content, visit the original source. Medical Xpress
Related articles

Patient-Owned Health Data Model Reduces Clinical Trial Recruitment Redundancy - The Clinical Trial Vanguard
The same patient, identified and re-consented for the third or fourth time across separate studies, is not an edge case. It is how clinical research is currently structured, and the inefficiency is measurable: every redundant records request, re-registration, and repeat consent conversation adds cost to the sponsor and time to a patient already managing a demanding diagnosis. The case building around patient-owned health data argues that the architecture itself is the problem, not the execution. The traditional model treats each protocol as a discrete relationship. A trial opens, participants are found, data flows inward, and the relationship ends. But sponsors rarely stop needing evidence from the same populations once a study closes. Observational work, real-world outcomes, label extensions, and post-market commitments all draw on the same patient groups, rebuilt from scratch each time. What the patient-owned model proposes instead is a single consented relationship that persists across those activities, turning what was an episodic research interaction into ongoing infrastructure.

WOAH Warns of Sharp Rise in Vector-Borne Disease Reports - Vet Candy
New global surveillance data reveal dramatic increases in reported bluetongue and West Nile fever events, raising concerns about climate change, expanding disease territories, and the future of animal health. The world's disease map is changing, and veterinarians are being urged to pay attention. From biting midges carrying bluetongue virus across Europe to mosquitoes spreading West Nile fever, vector-borne diseases are emerging in new regions, creating growing challenges for animal health professionals, livestock producers, and public health officials. The World Organisation for Animal Health (WOAH) issued a warning on October 9, 2026, calling for stronger disease surveillance, earlier detection, and better international cooperation as reports of several vector-borne diseases continue to climb. An analysis of information submitted through the World Animal Health Information System (WAHIS) reveals a particularly striking increase in reported exceptional epidemiological events since 2023. The findings suggest that shifting environmental conditions, changing vector populations, and animal movements are reshaping where certain infectious diseases can spread.
0 comments
No comments yet. Be the first to share your thoughts!